Generic Name and Formulations:
Tositumomab 35mg/vial, 225mg/vial; soln; Iodine I131 tositumomab 0.61mCi/mL, 5.6mCi/mL soln; both for IV infusion after dilution; preservative-free.
Indications for BEXXAR:
Non-Hodgkin's lymphoma (CD20 antigen-expressing relapsed or refractory, low grade, follicular, transformed, or rituximab-refractory).
See full labeling. Pretreat with acetaminophen 650mg and oral diphenhydramine 50mg and thyroid blockers; continue thyroid blockers 2 weeks after therapeutic dose. Give by IV infusion. Dosimetric step: Tositumomab 450mg over 1hr, then Iodine I131 tositumomab (containing 5mCi I131 and 35mg tositumomab) over 20 minutes. Therapeutic step (7–14 days after dosimetric step if biodistribution acceptable): tositumomab 450mg over 1hr, then calculated therapeutic dose of Iodine I131 tositumomab over 20 minutes. Reduce infusion rate by 50% if infusional toxicity occurs; stop if severe; may continue at 50% rate if severe symptoms resolve.
Hypersensitivity to murine proteins. Pregnancy (Cat.X).
Serious allergic reaction (including anaphylaxis). Prolonged and severe cytopenias. Radiation exposure.
Use only by physicians trained in radionuclide therapy. Handle and dispose of properly. See full labeling on patient contact restrictions. Not for initial treatment. Have medical and supportive care available. Permanently discontinue if serious allergic reactions develop. >25% lymphoma marrow involvement and/or impaired bone marrow reserve, platelet count <100000cells/mm3, neutrophil count <1500cells/mm3, or intolerant to thyroid blockers: not recommended. High tumor burden. Splenomegaly. Renal impairment. Screen for human anti-mouse antibodies (increases anaphylaxis risk). Obtain CBCs and platelet counts before and for up to 12 weeks after therapy. Monitor TSH (before and annually), serum creatinine (before). Use adequate contraception during and for 12 months after therapy. Elderly. Nursing mothers: not recommended.
Radionuclide (B-lymphocyte-restricted differentiation antigen [CD20] inhibitor).
Concomitant other forms of irradiation or chemotherapy: not recommended. Caution with live viral vaccines, anticoagulants, platelet aggregation inhibitors.
Thrombocytopenia, neutropenia, anemia, headache, asthenia, fever, chills, pain, GI upset, cough, pneumonia, pleural effusion, dehydration, rash, infection, hemorrhage, allergic reactions (may be fatal), myelodysplastic syndrome, secondary malignancies, antibody formation.
For technical questions call (877) 423-9927.
Dosimetric pack (tositumomab 2 x 225mg/vial + 1 x 35mg/vial and
Iodine I131 tositumomab 1 x 20mL single-use vial)—1; Therapeutic pack (tositumomab 2 x 225mg/vial + 1 x 35mg/vial and Iodine I131 tositumomab 1 or 2 x 20mL single-use vial)—1
Neurology Advisor Articles
- Higher Levels of Cholesterol May Protect Men From Parkinson Disease
- Ajovy Injection Approved for Migraine Prevention in Adults
- Chronic Pain May Be Contributor to Suicide
- FDA Approves Tiglutik for the Treatment of Amyotrophic Lateral Sclerosis
- Natalizumab Improves Cognitive Function in Multiple Sclerosis
- 5 Key Findings Presented at 2018 Parkinson Disease Conference
- Parkinson Disease and the Gut: Treatment Potential Abounds
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Stroke-Code Patients With Low NIHSS Score, No Acute Imaging Findings Often Misdiagnosed
- Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment
- New 15-Item Dyspnea-ALS-Score Assesses Dyspnea in ALS
- CDC: About One in Five U.S. Adults Have Chronic Pain
- Fingolimod Cuts Multiple Sclerosis Relapses in Pediatric Patients
- Gains in Insurance Coverage Seen for Lesbian, Gay, Bisexual Adults
- Brivaracetam Effective for Reducing Seizures in Patients with Epileptic Encephalopathies